



# Quantifying Phage- Bacteria Dynamics In Vitro

Rapid Emergence of Phage-Resistant  
*Klebsiella pneumoniae*

Research Seminar | August 2025

Presented by Maxymia

# Executive Summary

## Problem

Multidrug-resistant *Klebsiella pneumoniae* represents a critical public health threat, necessitating alternatives to conventional antibiotics

## Method

Combined in vitro experimentation with mathematical modeling to quantify population dynamics between bacteria and phage


## Key Results

Phage-resistant mutants emerge rapidly and show no fitness cost ( $\gamma \approx 0.58 \text{ h}^{-1}$ ), comparable to susceptible strains

## Significance

Provides critical parameters for designing effective phage therapies and highlights the challenge of bacterial resistance

# Background & Motivation



## The Antibiotic Crisis

Rising antimicrobial resistance threatens our ability to treat common infections, with phage therapy emerging as a promising alternative


## The Knowledge Gap

Effective phage therapy requires understanding interaction kinetics, yet critical parameters—particularly resistance emergence rates—remain poorly quantified


## Our Focus

Determining the key parameters governing *K. pneumoniae* interaction with bacteriophage vB\_Kpn\_2-P4 to inform therapeutic strategies

# Research Questions & Objectives



Primary Question: Can we quantify the key parameters of phage-bacteria co-evolution in a clinically relevant strain?



# Materials & Experimental Design

## Bacterial Strain

*Klebsiella pneumoniae* Kpn63

- Clinical, carbapenem-resistant isolate
- High-risk clone (KL-64, ST-147)

## Bacteriophage

vB\_Kpn\_2-P4

- Lytic phage with broad host range
- Selected for activity against Kpn63

## Experimental Protocol

- 96-well plate format
- OD<sub>600</sub> measurements every 10 minutes
- 16.5-hour monitoring period

## Experimental Sets

- Bacteria-only: 8 replicates × 4 initial ODs
- Phage-bacteria co-culture: 21 replicates

# Methodology



## Experimental Data

Time-series  $OD_{600}$  measurements of bacterial growth with and without phage

## Mathematical Models

Bacterial Growth: Logistic model ( $k, C$ )


Phage-Bacteria: 4-component ODE system tracking susceptible, infected, resistant bacteria, and phages

## Parameter Estimation


- Levenberg-Marquardt algorithm
- Bayesian Inference

## Parameter Validation

Cross-validation between methods to ensure robust estimation



# Results: Rapid Resistance Emergence



$0.58 \text{ h}^{-1}$   $0.45-0.55$

Resistant Growth Rate

Nearly identical to susceptible strain  
( $0.54 \text{ h}^{-1}$ )

170-226

Phage Burst Size

New virions released per lysed cell

Resistance Emergence

High probability of de novo resistant  
mutants

0.96

Infection Rate

High phage effectiveness against  
susceptible cells

# Comparison to Published Data

Parameter	This Study	Literature Values	Reference
Growth Rate (k)	0.54 $\text{h}^{-1}$	0.75 $\text{h}^{-1}$ ( <i>P. aeruginosa</i> )	Rodriguez-Gonzalez et al.
Burst Size ( $\beta$ )	170-226	32-303	Various Kpn phage studies
Infection Rate ( $\rho$ )	0.96	0.85-0.99	Phage-bacteria models
Resistance Rate ( $\mu$ )	0.45-0.55	Highly variable	Limited comparable data

ⓘ **Unique Contribution:** Complete integrated parameter set for a clinically relevant carbapenem-resistant *K. pneumoniae* strain and its phage

# Error Analysis & Limitations

## In Vitro vs. In Vivo Translation

Parameters quantified under laboratory conditions may differ from those in actual infection environments

- Absence of immune system factors
- Homogeneous environment vs. tissue heterogeneity

## Model Simplifications

Mathematical framework necessarily omits some biological complexities

- Spatial heterogeneity not accounted for
- Assumes uniformity in phage-bacteria interactions

## Statistical Uncertainty

Parameter variations between estimation methods

- Burst size:  $\beta = 226$  (LM) vs. 170 (BI)
- Increasing replicate variability over time

# Implications for Phage Therapy

## Monotherapy Limitations

Rapid emergence of "no-cost" resistance suggests single-phage approaches likely to fail quickly

## Parameterized Models

Quantified rates enable sophisticated computational models to test therapeutic strategies *in silico*

## Strategic Approaches

- Phage cocktails targeting multiple receptors
- Phage-antibiotic synergy to suppress resistance
- Sequential phage administration strategies

